N/A N=15 Human Papillomatosis Genotyping of Children in Thailand
Recurrent Laryngeal Papillomatosis · Human Papilloma Virus
Primary: Human Papillomavirus Genotypes — 6; 9 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Malignant Neoplasms of Brain
Primary: Humoral and Cellular Immune Response — 3; 0; 7 participants
N/A N=637 Transforming Research and Clinical Knowledge in TBI Pilot
Traumatic Brain Injury
Primary: Glasgow Outcome Scale Extended (GOSE) — 7; 5 Glasgow Outcome Scale Extended (GOSE)
Phase 2 N=26 Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer
Prostate Cancer
Primary: Number of Participants Showing a 50% Reduction in Serum Prostate Specific Antigen(PSA) During Treatment — 0 participants
N/A N=30 Effects of Mirror Neurons Stimulation on Motor Skill Rehabilitation in Children With Cerebral Palsy
Children With Spastic Diplegia, Between the Ages of 2 to 10 Years · Gross Motor Function Classification System (GMFCS) Level I,II and III
Primary: The Gross Motor Function Measure (GMFM-66) Score at Entry, the Second and the Sixth Month. — 44.8; 49.4; 54.7; 57.5 Scores on a scale — p=0.34
N/A N=99 School-Based Preventive Asthma Care Technology: A Trial Using a Novel Technology to Improve Adherence
Asthma
Primary: Average Number of Symptom-free Days Over 14 Days; (Symptom-free Days Are Averaged Over 4 Bi-monthly Follow-ups) — 11.33; 10.40 Days
Phase 2 N=94 A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement
Post Operative Pain
Primary: SPID-12 — 2.87; 1.28; 12.66; -7.39 units on a scale — p=0.194
Phase 4 N=20 Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof
Cataract
Primary: Best Corrected logMAR Contrast Acuity at Photopic/Mesopic Condition — 0.34; 0.34 log MAR
Phase 3 N=722 Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
Hepatitis B
Primary: Percentage of Participants Receiving Subcutaneous Vaccination Who Achieved Seroprotection — 90.1; 82.5 Percentage of participants
Phase 2 N=25 Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Progression-free Survival — 12 Weeks
Phase 4 N=180 A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
Heart Failure, Congestive
Primary: Percent Change From Baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) at Week 26 — 8.02; 9.50 Percent change
N/A N=482 Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)
HIV Infections
Primary: Percentage of Participants Receiving Antiretroviral Treatments Administered With Raltegravir — 44.4; 14.0; 1.3; 15.7 Percentage of participants
Phase 2 N=12 Extension of the MIME Robotic System for Stroke Rehabilitation
Stroke · Impaired Upper Extremity Function
Primary: Fugl-Meyer Test of Motor Function — 1.9; .8; 1.3; .8 units on a scale
N/A N=22 Investigation of the Performance and Safety of New 1-piece Open Ostomy Appliances Compared to Standard Care
Ileostomy - Stoma
Primary: Degree of Leakage — 4; 4.6; 2.6 units on a scale
Phase 4 N=148 Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
Depression
Primary: Depression as Assessed by the Quick Inventory of Depressive Symptomatology-Self Rated 16 (QIDS-SR-16) — 6; 16 participants